

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/797,927	:
Filing Date	March 8, 2004	_
First Named Inventor	Val Goodfellow	
Art Unit	1614	
Examiner Name		
Attorney Docket No.	690068.575	

		· · · · · · · · · · · · · · · · · · ·			
	El	NCLOSURES (check all that a	oply)		
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement; Form PTO-1449 Cited References Certified Copy of Priority Document(s) Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 Response to Missing Parts/Incomplete Application		Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Ci		After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Other Enclosure(s) (please identify below):	
<u>Remarks</u>					
<u>. </u>					
	SIGNATUR	RE OF APPLICANT, ATTORNE	, OR A	GENT	
Firm Name Seed Intellec		tual Property Law Group PLLC		Customer Number 00500	
Signature		///			
Printed Name Karl R. Herma		anns		***	
Date 01/03		7/05 Reg	No.	33,507	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.					
Signature		(
Typed or printed name Jaso		on Añover	Date	1/03/05	
This collection of information i	e required by 37 CER 1.5	The information is required to obtain or retain a be	ofit by the or	blic which is to file (and by the LISPTO to	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35U.S. 222 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ifw

PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22313-1450.

Date 3, 2005

Jason Añover

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Val Goodfellow et al.

Application No.

10/797,927

Filed

March 8, 2004

For

MELANIN-CONCENTRATING HORMONE RECEPTOR

ANTAGONISTS AND COMPOSITIONS AND METHODS

RELATED THERETO

Art Unit

: 1614

Docket No.

690068.575

Date

: January 3, 2005

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449. Copies of the cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of all other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the

Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Karl R. Hermanns

Registration No. 33,507

Enclosures:

Postcard Form PTO-1449 Cited References (13)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

546028

FORM PTO-1449 (REV.7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

SCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO. 690068.575

APPLICATION NO. 10/797,927

APPLICANTS

Val Goodfellow

FILING DATE March 8, 2004 GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2002/0052383	05/02/02	Bakthavatchalam et al.	514	255.03	
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

	1	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
	DOCUMENT NOMBER		DATE	COONIKI	YES	NO
	AE	WO 01/21169 A1	03/29/01	WIPO		
	AF	WO 01/21577 A2	03/29/01	WIPO		
,	AG	2001-226269	08/21/01	JP (+ Abstract in English)		
;	АН	WO 01/82925 A1	11/08/01	WIPO		
	AI	WO 01/87834 A1	11/22/01	WIPO		
	AJ	WO 01/94368 A1	12/13/01	WIPO		
	AK	WO 02/04433 A2	01/17/02	WIPO		
	AL	WO 02/06245 A1	01/24/02	WIPO		
	АМ	WO 02/059108 A1	08/01/02	WIPO		
	AN	WO 02/070511 A1	09/12/02	WIPO		
	AO	WO 03/031410 A1	04/17/03	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP			Bednarek, M., et al., "Synthesis and Biological Evaluation in Vitro of a Selective, High
			Potency Peptide Agonist of Human Melanin-concentrating Hormone Action at Human
			Melanin-concentrating Hormone Receptor 1," J. Biol. Chem. 277(16):13821-6, April 19,
,			2002.
AQ			Takekawa, S., et al., "T-226296: a novel, orally active and selective melanin-concentrating
			hormone receptor antagonist," Eur J Pharmacol. 438(3):129-35, March 8, 2002.

EXAMINER

DATE CONSIDERED

^{*} EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)